Life Sciences Archive » September, 2013

Life Sciences - September, 2013

235 articles

• MLB Drug Clinic May Face Fla. Criminal Suit
• Bristol-Myers, Citigroup Hit In $27M NJ Superfund Suit
• RyMed Prevails In Rival's Catheter Connector Patent Suit
• Safeway Rehashed Doryx Antitrust Claims In New Suit: Judge
• NIH Cleared To Fund $128M Anthrax Research Lab In Boston
• Ex-Adviser Cops To Insider Trading Tied To $11B Pharma Deal
• FDA To Halt Inspections, Dial Back Enforcement In Shutdown
• Clinton Group Buys More Nutrisystem, Asks Higher Dividend
• Paxil Birth Defect Suit Sent Back To Pa. State Court
• Senate Nixes House Spending Resolution As Shutdown Looms
• Biomet Sued Over $3M Scheme To Steal Stryker Sales Reps
• Aspen Puts Up $1B For Pair Of GSK Blood Thinners
• ACLU Slams DEA In Prescription Records Privacy Fight
• Plavix Hemorrhage Complaints Growing In NY State Court
• Deals Rumor Mill: Lloyds, Glencore, Twitter
• NJ Court Reinstates Bristol-Myers Wrongful Death Suits
• Pa. Judge Denies GSK's Attempts To Nix Thalidomide Suits
• GSK Can't Shake Antitrust Claims Of Drug Discount Abuse
• Diabetes Supplement Co.'s Expert 'Incoherent,' Judge Says
• FDA OKs Boxed Death Risk Alert For Pfizer Antibiotic
• Medtronic Nets $10M Settlement To End Insulin Pump Fight
• 5 Takeaways From FDA's Unique Device ID Rule
• Md. Negligence Doctrine Gives Takeda Win In Actos Suit
• FTC OKs Actavis' $8B Warner Chilcott Buy With Conditions
• Nexium Case Begins To Define Contours Of Actavis Decision
• FTC Demands Drug Divestment For $1.9B Mylan, Agila Merger
• Fed. Circ. Nixes Dr. Reddy's Patent Win On Generic Lunesta
• Siemens Settles Class Action Over HearUSA Stock Price
• Landauer Pursues Ch. 11 Plan After Stalking Horse Debt Buy
• House, Senate Panels Agree On Compounder Oversight Bill
• FDA Says Drug Companies May Be Abusing Petition Process
• Obviousness Of Claims: Common Sense Alone Is Not Enough
• How To Respond When FDA Knocks
• Rakoff Scolds Lupin For 'Fecklessness' In Antara Patent Row
• Nobel Fights $4M Attys' Fee Bid In Dental Implant Suit
• FDA Rips Unsanitary Practices Of India Drug Co. In Mylan Buy
• Par, Purdue Settle IP Claims In OxyContin Antitrust MDL
• Drug Comparison Suits May Drive Shift In Pharma Ads
• IP Group Asks High Court To Keep Burden On Licensees
• How To Avoid Pitfalls Of Hiring Gov't Officials' Relatives
• Pfizer Unit Wins $60M HHS Contract For Nerve Gas Treatment
• Skadden Reps Stryker In $1.65B Surgical Robotics Co. Buyout
• EU Parliament Committee OKs Special Medical Device Checks
• Hazy FDA Rules Cloud Medical Food's Future
• AngioDynamics Renews Bid For Biolitec Sanctions In IP Row
• 9th Circ. Affirms Remand Of Painkiller Suit To State Court
• 7 Takeaways From FDA's Mobile Medical Apps Guidance
• Cephalon Mustn't Talk IP At Pay-For-Delay Trial, FTC Says
• Hungarian Drugmaker Egis Draws $483M Offer From Servier
• DePuy Hits 2 Ex-Employees With Breach Of Contract Suit
• BigLaw IP Partner ID'd As Alleged Drunk Tipster In SEC Case
• GSK's Data Woes A Warning For Others, NY Judge Says
• Forest Sues Mylan, Others To Block Generic Savella
• Rite-Aid, Wal-Mart Can't Shake Glucosamine False Ad Suit
• Mensing Doesn't Nix Generic-Fosamax Claims, 3rd Circ. Told
• Applying Double-Patenting Safe Harbor After St. Jude
• A New Era Of Post-Plea Compliance Obligations
• And Now A Word From The Panel ...
• Pay-For-Delay Ruling May Be Boon For Attys, Experts Say
• Murky HIPAA Marketing Guidance Creates Costs Headache
• Vista Equity Buys Medical Software Co. For $644M
• Novartis Challenges $1.3M Verdict In Zometa Jaw Injury Suit
• 1st Hip Implant MDL Bellwether Against J&J Delayed Again
• Oxycontin Patents Not Infringed, Drug Cos. Say At Trial
• Biomaterial Co. MiMedx Accused Of Defrauding Investors
• Risperdal Marketing Appeals Dropped In Pa. Appeals Court
• GE, Lilly Rip Proposed Biz Method Patent Review Expansion
• A Snapshot Of The Anti-Bribery Enforcement Landscape
• FDA Overhauls Painkiller Patch Labels After Child Deaths
• FDA Finalizes Long-Sought Mobile Medical Apps Guidance
• Myriad GC Soft-Pedals Importance Of High Court IP Ruling
• AbbVie Will Pay Up To $840M For Ablynx Licensing Deal
• Nordion Settles $90M Mad Cow Contamination Suit
• Amgen Scores Sweet BofA Debt Terms In $10.4B Onyx Deal
• 2nd Circ. Won't Rehear Schemer's $10M Morgan Stanley Case
• HIPAA Revisions Arrive Amid Lingering Confusion
• Cancer Drug Firm Ducks Shareholder Suit Over $26M Offering
• Biosimilars Don't Deserve Unique Name, Group Tells FDA
• Tipsy Lawyer Disclosed Secret $3.6B Pfizer Deal, SEC Says
• HHS Clarifies Pay Rules For 3rd-Party Refill Reminder Cos.
• FDA Issues Final ID Rule For Medical Devices
• Jury Orders Becton To Pay $114M In Syringe Antitrust Case
• Nautilus Takes Heart Rate Monitor IP Case To High Court
• How Lawyers Can Effectively Build A Reputation Online
• Post-Acute Sector Deal Activity Increases In 2013
• LOM Medical Shareholders Lose Bid For New Board Election
• Sanofi Settles Obesity Drug Class Action For $40M
• 4 Ways To Make Sure Comments On Agency Rules Count
• Investor Says Chiesi 'Coerced' Cornerstone Into $255M Buyout
• Fla. Medical Device Co. Accused Of Misleading Investors
• The Novel And Emerging Scholastic Privilege
• Burden Of Proof On Patent Licensees, High Court Told
• Mich. AG Floats Compounding Pharmacy Reform Bill
• Univ. Of Pittsburgh Fires Up Cell-Incubation Patent Suit
• Deals Rumor Mill: Roche, JPMorgan, Goldman Sachs
• Amgen's $10B Onyx Deal Gets Antitrust Approval
• Sanofi Accused Of Shorting Staff For Sales Of Cancer Drug
• Medtronic Breach Claims Not Time-Barred, DuPont Says
• Ex-Banker Admits To Hiding Money In $1.7B Olympus Fraud
• 3rd Circ. Adopts Unheard-Of Consumer Class Action Hurdle
• How In-House Counsel Avoid Breaking Bad As Biz Advisers
• High Court Urged Not To Take Novo Foreign Liability Case
• House Small-Business Panel OKs GOP Regulatory Reform Bill
• GSK Asks 9th Circ. For New Trial After Gay Juror Booted
• Drug Repackager To Halt Practices After FDA Mislabeling Suit
• Masimo Faces Sanctions Bid Over Discovery In FCA Fight
• J&J Says $175M Shareholder Suit Requires Board Approval
• Rainmaker Q&A: DLA Piper's Stasia Kelly
• Abbott Moves To Toss Humira Suit Following Court's Sidestep
• A Powerful Tool To Effectively Fight Fraud
• Travelers Fights Cephalon Bid To Nix $22M Marketing Suit
• 8th Circ. Urged To Revive CMS Bidding Program Dispute
• Boston Scientific Settles Coronary-Stent Patent Disputes
• Edwards' Invalidity Claims Tossed In Nerve-Tech Patent Row
• Supreme Court Asked To Weigh Hospira Drug-Shortage Suit
• Mass. PE Firm Takes Majority Stake In Pharmacy Software Co.
• Dukes Prevents Class Cert. In Nexium MDL, AstraZeneca Says
• Deals Rumor Mill: Repsol, Lloyds, Total
• Novartis Beats Subpoenas In Jaw-Injuries Drug Suit
• Baxter Wins Bid To Compel FDA Testimony In Plasma MDL
• Warner Chilcott Sued Over Loestrin Pay-For-Delay Scheme
• Resveratrol Supplement Maker Sued Over 'Organic' Claims
• FDA Blocks Imports From Another Ranbaxy Drug Plant
• Boston Scientific Hit By Inventor's $570M Contract Suit
• Investors Sue Fertility Treatment Co. Following FDA Letter
• 6th Circ. Asked To Revive Cleanup Suit Against GSK, Coke
• CORRECTED: FTC's Brill Vows To Fight Against Pay-For-Delay
• Epstein Becker Nabs Ober Kaler Health Care Pro
• Morgan Lewis Guides Chiesi In $255M Cornerstone Takeover
• Navigating Conflicts When Serving 3rd-Party Subpoenas
• Arthrex Asks High Court To Nix $85M Suture Patent Verdict
• Pfizer Wants High Court To Review 1st Circ. RICO Rulings
• House Bill Would Revamp Compounding Pharmacy Oversight
• Pfizer Urges 3rd Circ. To Uphold Alzheimer Drug Ruling
• AstraZeneca Can't Block Generic Nexium During Appeal
• Wal-Mart Charged Premium For Migraine Meds, Suit Says
• Whistleblower Wants Cephalon FCA Suit Moved To Pa.
• Covidien IV Disinfectant Caps Targeted In Patent Suit
• Merck, BMS Target Aurobindo Over Generic HIV Drug
• Chinese Authorities Eye Bayer Amid Pharma Bribery Probe
• 10 Reasons You Should Value Your Chief Compliance Officer
• An Update On Resale Price Maintenance in China
• Eli Lilly Levels $500M Attack On Canadian Patent Law
• AstraZeneca Can't Dodge Nexium Antitrust Claims
• FTC Wants Access To Boehringer Docs In Pay-For-Delay Probe
• Landauer, Creditors Settle Differences Over Ch. 11 Sale
• Fed. Circ. Nixes Pronova's Patent Win Against Teva, Par
• Spotlight On Spoliation
• Ensure Drink Maker Can't Dodge False Ad Suit
• Fed. Circ. Clears Medtronic In Gore Stent Patent Case
• $886M Otsuka Buyout Cheats Astex Investors, Suit Says
• HHS Will Launch Guidance On HIPAA Health Privacy Rules
• Pharmacists' Groups Sue Maine Over Drug Importation Law
• FDA Floats Drug Assessment Guidelines For Pharma Cos.
• Landauer Slams Creditors' Objections To Ch. 11 Sale Process
• BioSante Freed From 2 Investor Suits Over Libido Drug
• St. Jude Patent Not Shielded By Safe Harbor, Fed. Circ. Says
• Docs In Cephalon Pay-For-Delay Row Protected, Judge Says
• Quest Diagnostics Ducks ERISA Suit Over Severance Benefits
• Herbalife Exploits Hispanics, Latina Group Tells FTC
• Boiron Faces New False Ad Suit Over Homeopathic Flu Drug
• Allergan Asks Fed. Circ. For Block On Generic Zymaxid
• FDA Guidance Smoothes Advair Generic Approval Process
• How Courts Consider Patent Injunction's Impact On Public
• Travelers Again Told To Surrender Docs In Heparin Suit
• 8th Circ. Urged To Reopen Stryker FCA Pain Pump Suit
• In-House Counsel To Firms: Do More With Less
• Pfizer Denied Interlocutory Appeal In Pay-For-Delay MDL
• EU Approves Hospira's Inflectra In Biosimilars Milestone
• Medicare Could Collect Billions Via Drug Co. Rebates: OIG
• Bristol-Myers Squibb GC Notches Corporate Practice Award
• Patent Infringement Can Be Anti-Competitive, Judge Rules
• 5 Tips For Fattening Firm Wallets In Lean Times
• Okla. Appeals Court Backs $15M Award In Botox Injury Case
• FDA Overhauls Opioid Painkiller Labels, Urging Careful Use
• In NJ, 'Watchdog' Employees Can Get Protection Too
• Agilent Probes China Misconduct, Possible FCPA Violations
• Conclusory Allegations Won't Cut It Under FCA
• Attys Ask Fed. Circ. For More Fees In TheraSense Suit
• Sandoz Agrees To Shelve Plans For Generic Zetia
• Biogen Pays $100M In New Isis Pharma Alliance
• Courts Rein In FCA Suits Over Medicare Billing Mistakes
• The 4 Firms In-House Counsel Fear The Most
• NJ's Top Gov't Fraud Prosecutor Returns To Lowenstein
• UCB Beats Apotex's IP Suit Over Drugmaking Process
• GSK, Teva Say Lamictal Deal Doesn't Break Antitrust Law
• Japan's Suntory Spends $2B On Glaxo UK Drink Brands
• Why Growth In Nanotechnology Matters To Insurers
• Synbias Co-Owns Cancer Drug IP, Can't Be Sued, Judge Rules
• US Investigates GSK Following Chinese Bribery Claims
• Avanir Settles With Wockhart Over Planned Nuedexta Generic
• Health Privacy Rules Ruining Business, Contractor Says
• 3 Must-Watch Issues For Drug Cos. In 2013's Final Stretch
• Class Cert. Denied In Purdue Pharma Spam Fax Suit
• Deals Rumor Mill: Verizon, Johnson & Johnson, KKR
• Rainmaker Q&A: Faegre's Morgan Burns
• Jury Clears Breast Implant Maker Of Trade Secrets Claims
• FDA Staff Says GSK Is Missing Data On Pulmonary Drug
• China's 1st Step Toward More Participation In Rulemaking
• NJ Appeals Court Affirms Merck Win In Sewer Rights Case
• AstraZeneca Asks Fed. Circ. To Reopen Nexium Patent Suit
• FDA Vows To Speed Up Some Medical Device Guidance
• Warner To Pay Mylan $12M In Damages After Doryx IP Row
• Australian Antitrust Agency OKs Baxter's $4B Gambro Buy
• Deals Rumor Mill: Suntory, America Movil, TDR Capital
• Cash Offsets Count As Monetary Gain, 3rd Circ. Says
• Genentech Sues Rivals Over Generic Anti-Viral Drug Plans
• Funding Gap For Life Science Cos. Is Still A Problem
• Calif. Legislature Sends Biosimilar Drug Bill To Gov.
• 'Watchdog Employees' Can Claim Retaliatory Firing: NJ Court
• Doc Can't Block Bausch & Lomb's Slogan Use, Judge Says
• FDA Urged To Block Unapproved Post-Surgery Injections
• Otsuka Reaches $900M Deal For Oncology Drug Co. Astex
• Texas Inks $5M Deal With Drug Co. Over Medicaid Drug Prices
• Teva Pushes For Rehearing In Pa. Reglan Appeal
• Hospira Recalls IV Solution Following Hair Scare
• 3M Ducks Contract Suit Over $854M Pharma Unit Sale
• GenVec Ditches Liquidation Plan For Novartis Partnership
• Actavis Ducks Endo's Opana False Ad Suit In NJ
• PhRMA Backs Increased FDA Drug Import Controls
• BioMerieux Inks $450M Deal For Molecular Biology Co.
• Bartlett Doesn't Apply To Zometa Injury Suit, Judge Says
• Nutter McClennen Lands Ex-Fresenius Associate GC In Boston
• Can Antitrust Laws Prevent Abuse Of FDA Risk Programs?
• Weil Steers Bard In $262M Rochester Medical Buy
• Olympus Charged In UK Over $1.7B Accounting Fraud
• GSK China Allegedly Had A Hand In Bribery Scheme
• Doc's Errors Tainted Clinical Trial Data, FDA Says
• Deals Rumor Mill: Glencore, Warburg Pincus, Apax
• Lundbeck Fights $125M Pay-For-Delay Fine In EU
• Gilead Says New Hepatitis Drug Does Not Infringe Merck IP
• Takeda Again Sues Par Over Generic Gout Drug
• Bayer Can't Sink Whistleblower's Drug Kickback Claims
• Keeping Secrets Secret: A Primer On Economic Espionage
• A Broken Promise For Pharma Manufacturers